Fidelity Investments
JSPR icon

Fidelity Investments’s Jasper Therapeutics JSPR Stock Holding History

Fidelity Investments’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,949
Closed -$21.9K – 5507
2025
Q4 		$21.9K Buy
11,949
+50
+0.4% +$100 ﹤0.01% 4425
2025
Q3 		$28.3K Sell
11,899
-6,957
-37% -$21.1K ﹤0.01% 4217
2025
Q2 		$105K Buy
18,856
+3,842
+26% +$18.9K ﹤0.01% 3590
2025
Q1 		$64.6K Sell
15,014
-373,509
-96% -$2.49M ﹤0.01% 3744
2024
Q4 		$8.31M Buy
388,523
+350,162
+913% +$7.29M ﹤0.01% 2001
2024
Q3 		$722K Buy
+38,361
New +$764K ﹤0.01% 2716
2023
Q4 		– Sell
-10
Closed -$70 – 5551
2023
Q3 		$70 Buy
+10
New +$122 ﹤0.01% 4896

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Fidelity Investments's JSPR Position: Q1 2026 in Review

Fidelity Investments sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 11,949 shares — an estimated $21.9K sold.

Fidelity Investments first reported a position in JSPR in Q3 2023 and held it in 7 quarters. The position peaked at $8.31M in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Fidelity Investments reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 11,949 Jasper Therapeutics shares in Q1 2026, an estimated $21.9K.
  • Fidelity Investments first reported a position in Jasper Therapeutics in Q3 2023 and held it in 7 quarters.
  • Fidelity Investments's Jasper Therapeutics position peaked at $8.31M in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.